LONDON: The British regulator on Thursday approved the GlaxoSmithKline drug Sotrovimab to treat those at high risk developing severe Covid-19 symptoms, with the manufacturer said it “maintained activity” against the new Omicron variant.
Monoclonal antibodies “are found safe and effective to reduce the risk of hospitalization and death in people with covid-19-light infection which is at an increasing risk to develop severe diseases,” said medicines and health product regulation agencies.